News

Allecra kicks off with €15m
Enlarge image

FinanceFranceGermany

Allecra kicks off with €15m

19.04.2013 - Edmond de Rothschild and Forbion Capital Partners have co-led a Series A investment in anti-infectives company, Allecra Therapeutics.

Antibiotic resistance is a global problem, which has triggered huge investments into  development of new drugs against difficult to treat bugs. Yesterday,  Allecra Therapeutics GmbH started operations with a co-investment totalling €15m from Edmond de Rothschild Investment Partners, Forbion Capital Partners and EMBL Venture Funds. The German-French company (Loerrach, Saint Louis) aims to bring two novel antibiotics to clinical stage targeting multi-drug resistant gram-negative bugs such as Pseudomonas aeruginosa or Klebsiella pneumoniae. IP has been already in-licenced from Indian Orchid Chemicals & Therapeutics Ltd in Chennai.   

According to Orchid Chairman Raghavendra Rao, his company received a €1m upfront payment. „This is a big shot in arm for our drug discovery programme because we have been investing in basic R&D for some time now. We will be holding around 20% shareholding into that company and molecule and, as it progresses, we will get further revenues from it in the form of exit bonuses and further royalties.“ The Indian company recently reported progress in the antibiotic field boosting the performance of common antibiotics by application of silver nanoparticles provided by the fungus Trichoderma viridus. 

Allecra’s drug development will be based on a strategic partnership between Allecra’s founders headed by CEO Nicolas Benedict with Orchid. Allecra’s Board member Holger Reithinger from Forbion Capital said: “We have a specialist team, each of whom is deeply experienced in the development of antibiotics and which collectively is supported by a world-leading group of Opinion Leaders.” Board member Olivier Litzka from Edmond de Rothschild Investment Partners added: “Allecra’s strategic partnership with Orchid is an innovative collaboration bringing together Allecra’s strong development capability with Orchid’s track record in antibiotic research and manufacturing. This is a new company built on a solid foundation for success.”

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/allecra-kicks-off-with-eur15m.html

2014EU

19.12.2014 We took a look back at 2014: which European Biotechnology News stories topped the charts this year?

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

Events

All Events

Current issue

All issues

Product of the week

Products